2) 消化器癌における腫瘍マーカーの現状と今後の展望(シンポジウム 腫瘍マーカーの臨床的意義, 第485回新潟医学会)
- フォーマット:
- 論文(リポジトリ)
- 責任表示:
- 藍沢, 喜久雄 ; 畠山, 勝義 ; 酒井, 靖夫 ; 白井, 良夫 ; 塚田, 一博 ; 田中, 乙雄
- 出版情報:
- 新潟医学会, 1994-05
- 掲載情報:
- 新潟医学会雑誌 — 新潟医学会雑誌
- ISSN:
- 00290440
- 著者名:
藍沢, 喜久雄 畠山, 勝義 酒井, 靖夫 白井, 良夫 塚田, 一博 田中, 乙雄 - 巻:
- 108
- 通号:
- 5
- 開始ページ:
- 342
- 終了ページ:
- 348
- 概要:
- Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) have been routinely utilized in diagnosis and monitoring of patients with cancers of digestive organ (esophagus, stomach, gallbladder, biliary duct, pancreas, colon and rectum) in our division. They are clinically useful for diagnosis and evaluation of the clinical stage, status of lymph node and hematogenous metastasis, resectability, and detection of tumor reccurence in advanced cancer, … however, there are no diagnostic value for the detection of early cancer. The combined assay of these tumer markers has an advantage for increasing the positive rates for these cancers. Alpha-fetoprotein (AFP) measurement may be useful for the detection of AFP-producing tumors besides hepatocellular carcinoma, which are regarded as specific tumors with high malignant state. Monoclonal antibodies to some membrane-bound tumor associated antigens, oncogene products, growth factor receptors, or growth factor itself may be applied to immunotargeting therapy of human cancer or augmentation of the efficacy of anticancer drugs. Therefore, the development of the system for identification of these specific cell markers is becoming more important in an aid in therapy as well as in their use as indicators related to biological malignancy of cancer. 続きを見る
- E-Resources:
類似資料:
新潟医学会 |
金原出版 |
新潟医学会 |
中外医学社 |
新潟医学会 |
メジカルビュー社 |
新潟医学会 |
富士レビオ |
新潟医学会 |
新潟医学会 |
新潟医学会 |
新潟医学会 |